Project description
Novel device minimises complications in the treatment of diuretic-resistant congestive heart failure
Excessive accumulation of body fluid is a typical clinical symptom in congestive heart failure and chronic kidney disease patients. Presently, standard treatment involves the administration of diuretics. However, over one-third of patients are diuretic-resistant and require complicated procedures such as IV diuretic therapy, ultrafiltration therapy or peritoneal dialysis. The EU-funded IPUD project aims to develop the first implantable peritoneal ultrafiltration device for the continuous prevention of fluid overload. Controlled, moderate, non-aggressive fluid removal will eliminate the main complications associated with acute and aggressive treatments that lead to haemodynamic shock, worsening of renal function, arrhythmia and metabolic instability. The project will define the users’ requirements for the implantable unit, establish the back- and front-end software specifications and review the system’s development plan.
Objective
Fluid overload (congestion) is a classic clinical symptom and cause of distress among heart failure (HF) and chronic kidney disease (CKD) patients. Diuretics are currently the gold standard treatment but of the 26 million heart failure patients annually around the world, over one third are diuretic resistant. Current solutions for fluid overload in diuretic resistant patients such as IV diuresis, ultrafiltration therapy and peritoneal dialysis all carry complications and are acute treatments which do not prevent recurrence.
IPUD improves the clinical condition of fluid overloaded patients by continuously removing extracellular fluids with a unique implantable peritoneal ultrafiltration device, operating non-aggressively and independently from the kidneys’ function. IPUD is minimally invasive (laparoscopic approach) and the flat absorption device interfaces with the intraperitoneal membrane and applies a hydrostatic pressure gradient. It then continuously (24/7) and slowly absorbs systemic isotonic extracellular fluid and drains it to the urinary system preventing recurred accumulation. The device has a projected service life of 3 years and recharging the device has been made simple for the patients via wireless charging, needed on a weekly basis.
The global congestive heart failure treatment device market is worth almost $6 billion and is poised to grow at a CAGR of around 6.4% over the next decade to reach approximately $17.8 billion by 2025. IPUD will be sold directly to hospitals and clinics for approximately €30,000 through collaborations with the major distributors of heart failure devices.
Our senior team has over 50 years’ experience in the cardiology and medical device sectors combined with extensive academic education. We have raised €1 million in funding. Our full-time staff headcount is 4. Partnerships have been secured with several manufacturing subcontractors, including Sensirion in Switzerland, Inomec in Israel and Bossert Kast in Germany.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesclinical medicinecardiologycardiovascular diseasescardiac arrhythmia
- natural sciencesphysical sciencesclassical mechanicsfluid mechanicsfluid statics
- medical and health sciencesclinical medicinenephrologyrenal dialysis
- medical and health scienceshealth sciencesnutritionobesity
- medical and health sciencesclinical medicinenephrologykidney diseases
You need to log in or register to use this function
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
Nazareth
Israel
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.